| Description | Human CCNE1 knockout JIMT-1 cell line is edited by our special CRISPR/Cas9 technology. JIMT-1 cell line was established from a pleural effusion following postoperative radiotherapy in a 62-year-old ductal breast cancer in 2003.CO2 |
| Size | 1 vial (2*106 cells/vial) |
| Parental Cell Line | JIMT-1 |
| Biosafety Level | 1 |
| Format | Frozen |
| Culture Conditions | Cells are adherent cells that are cultured at 37℃ with 5% CO2. |
| Culture Medium | 90% Dulbecco's MEM + 10% FBS |
| Properties | Cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, desmin -, endothel -, EpCAM +, GFAP -, neurofilament -, vimentin - |
| Subculture Conditions | Split confluent culture 1:2 to 1:8 every 2-4 days using trypsin/EDTA |
| Derived From | Pleural effusion |
| Freezing Medium | 70% medium, 20% FBS, 10% DMSO |
| Subculture Guidelines | All seeding densities should be based on cell counts obtained by established methods. The recommended seeding density is at ca. 1*106 cells/80 cm2 at 37℃ with 5% CO2 cell harvest of ca. 8-10*106 cells/80 cm2. |
| Knockout Validation | Sanger Sequencing |
| Viability | >95% viability before freezing. |
| Adherent /Suspension | Adherent |
| Disease | Breast carcinoma |
| Purity | Immunogen affinity purified |
| Storage | Vapor phase of liquid nitrogen |
| Sterility | Mycoplasma negative, HOECHST and PCR |
| Shipping Info | Dry Ice |
| Species | Human |
| Tested Applications | Suitable for: ICC, WB, Sanger Sequencing |
| Tissue | Breast; Mammary gland |
| Recommended Control | Human wild-type JIMT-1 cell line |
| Doubling Time | Ca. 30-40 hours |
| Morphology | Epithelial-like cells growing in monolayers |
| Applications | For research use only |
| Product Type | Knockout Stable Cell Line |
| Price | Inquiry |
